Innovus Pharmaceuticals Announces First Commercial Shipment of Sensum+ to UK Partner

Innovus Pharmaceuticals Inc. (OTCQB:INNV) announced that its UK-based partner Tramorgan received its first commercial shipment of Sensum+(R).

As quoted in the press release:

On September 8, 2014 Innovus Pharma granted to Tramorgan an exclusive license to market and sell Innovus Pharma’s topical treatment to increase penile sensitivity in the U.K. Under the agreement, Innovus is eligible to receive up to approximately up to $44 Million in Upfront in Sales Milestone Payments plus 50% Royalties on Sales.

About Sensum+(R) and Reduced Penile Sensitivity:

Sensum+(R) is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+(R) (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+(R) was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+(R) twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.

Bassam Damaj, president and CEO of Innovus, commented:

This is the first entry to the European market and specifically to the U.K. market for our product Sensum+(R). Sensum+(R) is a patented and unique product for a large indication and we look forward to launch by our partner Tramorgan in the very near future.

Click here to read the full Innovus Pharmaceuticals Inc. (OTCQB:INNV) press release.